MX2023013140A - Vacunas contra el virus de la hepatitis b. - Google Patents
Vacunas contra el virus de la hepatitis b.Info
- Publication number
- MX2023013140A MX2023013140A MX2023013140A MX2023013140A MX2023013140A MX 2023013140 A MX2023013140 A MX 2023013140A MX 2023013140 A MX2023013140 A MX 2023013140A MX 2023013140 A MX2023013140 A MX 2023013140A MX 2023013140 A MX2023013140 A MX 2023013140A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- hepatitis
- vaccines against
- against hepatitis
- vaccines
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 208000002672 hepatitis B Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona inmunoterapias para infecciones por virus de la hepatitis B. Se proporcionan en la presente vectores de arenavirus genéticamente modificados adecuados como vacunas para la prevención y el tratamiento de infecciones por virus de la hepatitis B. También se proporcionan en la presente composiciones farmacéuticas y métodos para el tratamiento de infecciones por virus de la hepatitis B. Específicamente, aquí se proporcionan composiciones farmacéuticas, vacunas y métodos para tratar la infección por virus de la hepatitis B.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562250639P | 2015-11-04 | 2015-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023013140A true MX2023013140A (es) | 2023-11-28 |
Family
ID=57249796
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005569A MX2018005569A (es) | 2015-11-04 | 2016-11-03 | Vacunas contra el virus de la hepatitis b. |
MX2023013140A MX2023013140A (es) | 2015-11-04 | 2018-05-03 | Vacunas contra el virus de la hepatitis b. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005569A MX2018005569A (es) | 2015-11-04 | 2016-11-03 | Vacunas contra el virus de la hepatitis b. |
Country Status (22)
Country | Link |
---|---|
US (2) | US11214598B2 (es) |
EP (2) | EP4177348A1 (es) |
JP (3) | JP6914950B2 (es) |
KR (1) | KR20180082485A (es) |
CN (2) | CN108779472B (es) |
AU (2) | AU2016348675B2 (es) |
BR (1) | BR112018009032A8 (es) |
CA (1) | CA3003557A1 (es) |
DK (1) | DK3371316T3 (es) |
ES (1) | ES2934698T3 (es) |
FI (1) | FI3371316T3 (es) |
HK (1) | HK1255847A1 (es) |
HR (1) | HRP20221474T1 (es) |
HU (1) | HUE060648T2 (es) |
IL (1) | IL259077A (es) |
LT (1) | LT3371316T (es) |
MX (2) | MX2018005569A (es) |
PL (1) | PL3371316T3 (es) |
PT (1) | PT3371316T (es) |
SG (1) | SG11201803474UA (es) |
SI (1) | SI3371316T1 (es) |
WO (1) | WO2017076988A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8592205B2 (en) | 2007-12-27 | 2013-11-26 | Universitat Zurich | Replication-defective arenavirus vectors |
HUE054579T2 (hu) | 2013-12-03 | 2021-09-28 | Hookipa Biotech Gmbh | CMV vakcinák |
EP3778903A1 (en) * | 2014-11-13 | 2021-02-17 | Université de Genève | Tri-segmented arenaviruses as vaccine vectors |
WO2016198531A2 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
FI3371316T3 (fi) | 2015-11-04 | 2023-01-13 | Rokotteita hepatiitti b -virusta vastaan | |
CN108697775B (zh) | 2015-11-12 | 2023-05-09 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的沙粒病毒颗粒 |
DK3526323T3 (da) | 2016-10-14 | 2023-06-26 | Prec Biosciences Inc | Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet |
JP2022010188A (ja) * | 2017-02-03 | 2022-01-14 | 株式会社三洋物産 | 遊技機 |
JP2022010187A (ja) * | 2017-02-03 | 2022-01-14 | 株式会社三洋物産 | 遊技機 |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
KR20220041080A (ko) * | 2019-06-18 | 2022-03-31 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합 |
CA3143421A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
EP3990476A1 (en) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
KR102375703B1 (ko) | 2020-07-28 | 2022-03-17 | 경북대학교 산학협력단 | 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템 |
KR20240001135A (ko) | 2021-03-23 | 2024-01-03 | 후키파 바이오테크 게엠베하 | 전립선 암의 치료에 사용되는 아레나바이러스 |
WO2022226242A1 (en) * | 2021-04-21 | 2022-10-27 | La Jolla Institute For Immunology | Engineered arenavirus glycoprotein compositions, methods and use thereof |
CN113201051B (zh) * | 2021-04-27 | 2022-08-02 | 复旦大学 | 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用 |
AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
JPH1084967A (ja) | 1996-09-19 | 1998-04-07 | Fujirebio Inc | B型肝炎のe抗原 |
TR200102423T2 (tr) * | 1998-12-04 | 2002-02-21 | Biogen, Inc. | Peptid ligandları yoluyla bağlı birden fazla imünojenik bileşeni olan HBV çekirdek antijeni parçacıkları |
FR2803599B1 (fr) * | 2000-01-06 | 2004-11-19 | Inst Nat Sante Rech Med | Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications |
WO2006125983A1 (en) * | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
RU2478400C2 (ru) * | 2006-12-27 | 2013-04-10 | Эмори Юниверсити | Композиции и способы лечения инфекций и опухолей |
US8592205B2 (en) | 2007-12-27 | 2013-11-26 | Universitat Zurich | Replication-defective arenavirus vectors |
US10076570B2 (en) * | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
SG178254A1 (en) * | 2009-08-07 | 2012-03-29 | Transgene Sa | Composition for treating hbv infection |
WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
ES2646590T3 (es) | 2012-01-24 | 2017-12-14 | Sanford Health | Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos |
WO2014140301A1 (en) | 2013-03-15 | 2014-09-18 | Université De Genève | Anti-mycobacterial vaccines |
GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
HUE054579T2 (hu) | 2013-12-03 | 2021-09-28 | Hookipa Biotech Gmbh | CMV vakcinák |
WO2015183895A1 (en) | 2014-05-27 | 2015-12-03 | University Of Rochester | Novel arenavirus vaccine |
US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
WO2016048949A1 (en) | 2014-09-22 | 2016-03-31 | Regents Of The University Of Minnesota | Pichinde virus reverse genetics system and methods of use |
GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
EP3778903A1 (en) | 2014-11-13 | 2021-02-17 | Université de Genève | Tri-segmented arenaviruses as vaccine vectors |
DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
WO2016198531A2 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
WO2017068190A1 (en) | 2015-10-23 | 2017-04-27 | Institut Pasteur | Recombinant mopeia virus and vaccine platform |
FI3371316T3 (fi) | 2015-11-04 | 2023-01-13 | Rokotteita hepatiitti b -virusta vastaan | |
CN108697775B (zh) | 2015-11-12 | 2023-05-09 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的沙粒病毒颗粒 |
WO2017190074A1 (en) | 2016-04-28 | 2017-11-02 | The University Of Chicago | Lymphangiogenesis for therapeutic immunomodulation |
EP3458593A1 (en) | 2016-05-18 | 2019-03-27 | Hookipa Biotech GmbH | Tri-segmented pichinde viruses as vaccine vectors |
CA3039356A1 (en) | 2016-11-04 | 2018-05-11 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
EP3606549A1 (en) | 2017-04-07 | 2020-02-12 | Hookipa Biotech GmbH | Arenavirus particles to treat solid tumors |
-
2016
- 2016-11-03 FI FIEP16791573.5T patent/FI3371316T3/fi active
- 2016-11-03 MX MX2018005569A patent/MX2018005569A/es unknown
- 2016-11-03 SG SG11201803474UA patent/SG11201803474UA/en unknown
- 2016-11-03 US US15/773,512 patent/US11214598B2/en active Active
- 2016-11-03 KR KR1020187015548A patent/KR20180082485A/ko not_active Application Discontinuation
- 2016-11-03 DK DK16791573.5T patent/DK3371316T3/da active
- 2016-11-03 HU HUE16791573A patent/HUE060648T2/hu unknown
- 2016-11-03 AU AU2016348675A patent/AU2016348675B2/en active Active
- 2016-11-03 PT PT167915735T patent/PT3371316T/pt unknown
- 2016-11-03 CN CN201680077751.0A patent/CN108779472B/zh active Active
- 2016-11-03 ES ES16791573T patent/ES2934698T3/es active Active
- 2016-11-03 EP EP22201924.2A patent/EP4177348A1/en active Pending
- 2016-11-03 EP EP16791573.5A patent/EP3371316B1/en active Active
- 2016-11-03 WO PCT/EP2016/076591 patent/WO2017076988A1/en active Application Filing
- 2016-11-03 PL PL16791573.5T patent/PL3371316T3/pl unknown
- 2016-11-03 CN CN202211051785.6A patent/CN115948467A/zh active Pending
- 2016-11-03 HR HRP20221474TT patent/HRP20221474T1/hr unknown
- 2016-11-03 SI SI201631654T patent/SI3371316T1/sl unknown
- 2016-11-03 LT LTEPPCT/EP2016/076591T patent/LT3371316T/lt unknown
- 2016-11-03 JP JP2018541546A patent/JP6914950B2/ja active Active
- 2016-11-03 CA CA3003557A patent/CA3003557A1/en active Pending
- 2016-11-03 BR BR112018009032A patent/BR112018009032A8/pt active Search and Examination
-
2018
- 2018-05-01 IL IL259077A patent/IL259077A/en unknown
- 2018-05-03 MX MX2023013140A patent/MX2023013140A/es unknown
- 2018-11-22 HK HK18114923.3A patent/HK1255847A1/zh unknown
-
2021
- 2021-07-14 JP JP2021116562A patent/JP2021182922A/ja active Pending
- 2021-11-24 US US17/535,121 patent/US20220073568A1/en active Pending
-
2023
- 2023-01-10 AU AU2023200108A patent/AU2023200108A1/en active Pending
- 2023-10-19 JP JP2023180121A patent/JP2024010027A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
HK1251219A1 (zh) | 用於治療和預防乙型肝炎病毒感染的新的6,7-二氫吡啶並[2,1-a]酞嗪-2-酮類化合物 | |
CY1124288T1 (el) | Cmv εμβολια | |
PH12018500573A1 (en) | Hepatitis b core protein modulators | |
MX2017008720A (es) | Derivados y metodos para tratamiento de las infecciones por hepatitis b. | |
MX2019003525A (es) | Moduladores alostericos de proteina nucleo de hepatitis b. | |
JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
PH12016501379A1 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
PH12016501254A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
EA030115B9 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
EA201791460A1 (ru) | N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения | |
PH12017550022A1 (en) | Phosphoramidates for the treatment of hepatitis b virus | |
MX2017005252A (es) | Metodos para la preparacion de ribosidos. | |
EP3505620A4 (en) | 2D ORGANOID FOR INFECTIONS AND GROWTH OF HUMAN DIARRHOEVIRUS AND USE OF THE TWO-DIMENSIONAL ORGANOID | |
MX2017000312A (es) | Derivados de isoindolina para usarse en el tratamiento de una infeccion viral. | |
PH12017500817A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
EA201691835A1 (ru) | Аллостерические модуляторы капсидного белка гепатита в |